Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 22, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,411,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,605 pence per share; lowest price paid was 1,576 pence per share.
- Treasury Holdings (Settled): 503,095,912 shares (9.37% of total issued share capital).
- Treasury Holdings (Including Unsettled): 507,352,912 shares (10.43% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,864,783,498 shares.
Material Changes
The primary material change is the increase in the Company's treasury share holdings following the October 22 transaction. The total voting rights held in treasury now represent 10.43% of the Company's current total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in treasury (503,095,912 settled) against the latest Form 20-F or annual report.
- Confirm the calculation of total voting rights (4,864,783,498 shares in issue) for disclosure threshold assessments under FCA rules.
- Review the remaining authority for share repurchases under the mandate granted on May 1, 2013.